Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.
Lawmakers push for faster, conditional FDA approval pathway for rare disease drugs
As the FDA tightens its focus on rare disease treatments and speeding their entry to market, lawmakers on Capitol Hill are putting serious stock in
October 27, 2023